Skip to content

US · ONCY · BIOTECHNOLOGY

Oncolytics Biotech Inc. (ONCY) intrinsic value and stock valuation

$0.35as of 2026-11-21 · Mkt cap 80.54M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Oncolytics Biotech Inc. DCF and intrinsic value

InvestorsCraft values ONCY with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ONCY’s statements →

Oncolytics Biotech Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 oncolyticsbiotech.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-39.46M
20112025
Free cash flow
-$-27.6M
20112025
Total equity
-$-5.21M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-39.41M-$-34.98M-$-25.04M-$-20.68M-$-20.93M
Net income-$-39.46M-$-31.71M-$-20.56M-$-19.08M-$-20.98M
EPSd-$-411.64K-$-414.62K-$-304.05K-$-328.8K-$-392.08K
Operating cash flow-$-27.6M-$-26.97M-$-28.45M-$-23.36M-$-22.43M
Capital expenditure-$-10K-$-240K-$-10K-$-60K-$-290K
Free cash flow-$-27.6M-$-27.2M-$-28.46M-$-23.41M-$-22.72M
Total assets$10.4M$20.2M$38.8M$37.3M$45.9M
Total debt$770K$1.06M$420K$370K$660K
Net debt-$-6.37M-$-14.88M-$-34.49M-$-11.29M-$-40.61M
Total equity-$-5.21M$5.98M$27.6M$26.5M$36.1M
Cash and short-term investments$7.14M$15.9M$34.9M$32.1M$41.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$70K$90K$300K$300K$360K
Gross profit-$-70K-$-90K-$-300K-$-300K-$-360K
Research and development expenses$18.3M$21.7M$13.1M$11.9M$10.3M
Selling, general and administrative expenses$21.2M$13.3M$11.6M$8.53M$10.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$39.4M$35M$24.7M$20.4M$20.6M
Cost and expenses$39.4M$35M$25M$20.7M$20.9M
Interest income$530K$1.2M$1.33M$530K$100K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$100K$100K$300K$300K$360K
Ebitda-$-39.41M-$-34.88M-$-20.19M-$-18.71M-$-20.58M
Operating income-$-39.41M-$-34.98M-$-25.04M-$-20.68M-$-20.93M
Total other income/expenses, net$60K$3.4M$4.55M$1.67M-$-20K
Income before tax-$-39.35M-$-31.58M-$-20.49M-$-19.01M-$-20.94M
Income tax expense$110K$130K$70K$60K$40K
Net income-$-39.46M-$-31.71M-$-20.56M-$-19.08M-$-20.98M
Weighted average shares outstanding$95.9M$76.5M$67.6M$58M$53.5M
Weighted average diluted shares outstanding$95.9M$76.5M$67.6M$58M$53.5M
Balance sheet
20252024202320222021
Cash and short-term investments$7.14M$15.9M$34.9M$32.1M$41.3M
Net receivables$790K$70K$10K$520K$870K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$9.39M$18.9M$38.2M$35.7M$44.9M
Property, plant and equipment, net$1.01M$1.31M$650K$650K$980K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.01M$1.31M$650K$1.65M$980K
Total assets$10.4M$20.2M$38.8M$37.3M$45.9M
Accounts payable$4.81M$1.09M$1.08M$2.25M$590K
Short-term debt$260K$280K$130K$220K$290K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.37M$6.69M$4.24M$3.94M$2.69M
Long-term debt$510K$790K$290K$160K$360K
Deferred revenue, non-current$6.74M$6.73M$6.73M$6.73M$6.73M
Total non-current liabilities$7.24M$7.52M$7.02M$6.89M$7.09M
Capital lease obligations$770K$1.06M$420K$370K$660K
Total liabilities$15.6M$14.2M$11.3M$10.8M$9.78M
Common stock$0.00$438.2M$430.9M$404M$391.4M
Retained earnings-$-589.32M-$-477.71M-$-446M-$-418.25M-$-393.42M
Accumulated other comprehensive income (loss)$8.54M$960K$540K$660K$390K
Total equity-$-5.21M$5.98M$27.6M$26.5M$36.1M
Total investments$0.00$0.00$0.00$20.5M$0.00
Total debt$770K$1.06M$420K$370K$660K
Net debt-$-6.37M-$-14.88M-$-34.49M-$-11.29M-$-40.61M
Cash flow statement
20252024202320222021
Net income-$-39.46M-$-31.71M-$-27.75M-$-24.84M-$-26.3M
Depreciation and amortization$100K$420K$400K$390K$450K
Stock-based compensation$4.26M$2.72M$2.07M$2.38M$3.83M
Change in working capital$1.62M$3.54M$1.76M$390K-$-910K
Accounts receivable$4.03M-$-50K$510K$340K-$-780K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-27.6M-$-26.97M-$-28.45M-$-23.36M-$-22.43M
Investments in property, plant and equipment-$-10K-$-240K-$-10K-$-60K-$-290K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$-240K$20.2M-$-20.4M-$-290K
Common stock issued$19.4M$6.92M$31.6M$12.6M$32.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$19.4M$6.64M$32M$12.2M$33M
Net change in cash-$-8.06M-$-18.97M$23.3M-$-29.6M$10M
Cash at end of period$7.14M$15.9M$34.9M$11.7M$41.3M
Operating cash flow-$-27.6M-$-26.97M-$-28.45M-$-23.36M-$-22.43M
Capital expenditure-$-10K-$-240K-$-10K-$-60K-$-290K
Free cash flow-$-27.6M-$-27.2M-$-28.46M-$-23.41M-$-22.72M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Oncolytics Biotech Inc.

        Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

        CEO
        Jared Kelly
        Employees
        29
        Beta
        1.09

        Explore

        Frequently asked questions

        What is the intrinsic value of Oncolytics Biotech Inc. (ONCY)?

        InvestorsCraft does not currently publish an intrinsic value for ONCY. How the IC value is calculated.

        Is ONCY undervalued?

        InvestorsCraft does not publish an undervaluation signal for ONCY at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.